10-K: RxSight, Inc. Reports Strong Growth in 2024, Expands Market Share in Premium Cataract Surgery

RxSight, Inc. announces significant revenue increase and expansion in its LDD installed base, solidifying its position in the premium IOL market.

Summary

• RxSight, Inc., a medical technology company focused on improving vision after cataract surgery, reported its 10-K filing for the fiscal year ended December 31, 2024.
• The company's proprietary RxSight system is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery.
• In 2024, premium IOL procedures represented about 20% of all cataract procedures in the United States and generated approximately $810 million in revenue.
• The company's commercial efforts began in 2019 and have been primarily focused in the United States.
• As of December 31, 2024, RxSight had an installed base of 971 LDDs in ophthalmology practices and surgeons have implanted over 195,000 LALs since inception.
• The company plans to grow its business by expanding the LDD installed base and driving increased utilization of LALs.
• The company completed a 500-eye prospective, randomized, controlled multi-center Post Approval Study (PAS) in 2024, which was accepted by the FDA as fulfilling post-approval requirements.
• Research and development expenses were $34.4 million in 2024, $29.1 million in 2023 and $26.0 million in 2022.
• The company believes its current manufacturing capacity is sufficient to meet expected demand for at least the next 12 months.
• The company reported sales of $139.9 million for the year ended December 31, 2024, compared to $89.1 million for the year ended December 31, 2023.
• The company reported a net loss of $27.5 million for the year ended December 31, 2024, compared to a net loss of $48.6 million for the year ended December 31, 2023.
• As of December 31, 2024, the company had $237.2 million in cash, cash equivalents and short-term investments.
• The company believes its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and a decrease in net losses. However, the company is still operating at a loss and faces several risks, resulting in a moderate sentiment score.

Positives

• The RxSight system allows full customization and optimization of patient vision after surgery.
• Clinical trial results show superior visual outcomes with low risk of side effects.
• The RxSight system enables patients to preview and compare possible vision outcomes.
• The RxSight system empowers doctors to grow their practices with a premium IOL they can trust.
• The company has a large installed base of LDDs and a growing number of LAL implantations.
• The company has a vertically integrated manufacturing strategy offering control over product quality and rapid product iteration.
• The company has received approximately 40 supplemental approvals since initial FDA approval in November 2017.
• The company has a strong commercial organization focused on high-volume premium cataract surgeons.
• The company has a clear value proposition for patients, helping doctors to build their premium cataract practices.
• The company has a Post Approval Study (PAS) accepted by the FDA.
• The company's gross margin may continue to improve as manufacturing volume of LALs increases.

Negatives

• The company has a limited operating history.
• The company has a history of net operating losses and expects to continue to incur losses in the future.
• The price of the company's stock may be volatile.
• The company faces significant competition.
• The company depends upon third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of the RxSight system, making it vulnerable to supply disruptions and price fluctuations.
• The company may experience a significant disruption in its information technology systems or breaches of data security.

Risks

• The company may fail to effectively train its sales force, increase sales and marketing capabilities, or develop broad brand awareness in a cost-effective manner.
• The company may need to raise additional capital, which may not be available on acceptable terms, or at all.
• The company may be unable to successfully market and sell its RxSight system.
• The company may be unable to compete effectively.
• The company may experience difficulties in obtaining regulatory clearance or approval or in successfully marketing its products internationally.
• Global economic, political and market conditions may adversely affect the company's business, results of operations and financial condition.
• The company may be unable to obtain, maintain, protect and enforce patent and other intellectual property protection.
• The company may fail to obtain and maintain necessary regulatory clearances or approvals for its products.
• The company depends upon third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of the RxSight system.
• The company must recruit, retain, manage and motivate qualified executives as it builds out the management team.
• Future litigation proceedings could adversely affect the company's business.

Future Outlook

The company plans to grow its business primarily by expanding the size of its LDD installed base and driving increased utilization of its LAL through heightened awareness of the superior clinical outcomes its RxSight system provides patients. The company believes its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least the next 12 months.

Management Comments

• We believe our RxSight system provides doctors and patients increased confidence and peace of mind by eliminating the high-stakes preoperative guesswork common to competitive premium IOLs and allowing patients to iterate their final vision characteristics with customized post-surgical adjustments.
• We believe our RxSight system offers doctors and patients a significantly more reliable approach that can consistently deliver optimal, fully customized visual outcomes with few compromises, ultimately driving broad adoption and establishing it as the standard of care for premium cataract procedures.

Industry Context

The premium IOL market is projected to grow at a 12.0% CAGR by 2029, according to the Market Scope 2024 Premium Cataract Surgery Market Report. RxSight is focused on gaining market share in this growing segment by converting doctors and patients currently electing for conventional cataract surgery.

Comparison to Industry Standards

• In the pivotal study that formed the basis for our FDA approval, the observed rate of eyes with 20/20 or better uncorrected distance visual acuity for our LAL was 70.1%.
• This compares favorably to the results of pivotal studies with similar study designs and patient populations that supported FDA approval of Alcons Acrysof Toric (38.4%) and J&Js Tecnis Toric (43.6%).
• In FDA studies for the Alcon Panoptix, J&J Symfony and Alcon Vivity lenses, 48.8%, 59.2% and 17.0% of subjects, respectively, reported being bothered by halos postoperatively.

Legal Proceedings

• From time to time, we may become involved in litigation or other legal proceedings.
• We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.
• Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Stakeholder Impact

• The company's performance and future plans will impact shareholders, employees, customers, and suppliers.
• The company's success depends on its ability to attract and retain qualified personnel.
• The company's products aim to improve the vision of patients following cataract surgery.
• The company relies on third-party suppliers for components and subcomponents of its products.

Next Steps

• The company plans to grow its business primarily by expanding the size of its LDD installed base and driving increased utilization of its LAL through heightened awareness of the superior clinical outcomes its RxSight system provides patients.
• The company intends to continue to make investments in its sales and marketing organization, primarily sales representatives, clinical applications specialists and technical service personnel to support new customers and upgrades and LAL account managers to facilitate adoption of use of our LALs among existing accounts.
• The company will expand its marketing efforts with additional print and digital, social media and other customer tools to expand their local advertising.
• The company will also continue to make significant investments in research and development and clinical expenses to make enhancements in its current products.

Key Dates